Patch Testing During Immunosuppressive Therapy: A Systematic Review.
Journal
Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335
Informations de publication
Date de publication:
Historique:
pubmed:
27
4
2021
medline:
2
2
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
Patch testing, used in the assessment of allergic contact dermatitis, is ideally avoided in patients receiving immunosuppressive therapy because of concerns with reductions in accuracy; however, this is not well characterized in the literature. This systematic review summarizes patch testing results in patients receiving immunosuppressive therapy. We identified 16 studies, comprising 195 patients with dermatitis or psoriasis, who were patch tested while receiving immunosuppressants. Of these, 7 studies, comprising 85 patients with dermatitis, patch tests were performed before and during immunosuppression. Overall, 67.9% (n = 19) of the dermatitis patients receiving dupilumab maintained positive reactions to an allergen that previously graded as a 2+/3+ reaction. Several immunosuppressants were also associated with positive patch test results for various allergens. These include dupilumab, cyclosporine, and low-dose prednisone (≤10 mg/d) for dermatitis, and tumor necrosis factor α inhibitors, ustekinumab, and methotrexate for psoriasis. Ideally, it is preferable to patch test when patients are not receiving oral immunosuppressants or immunomodulators. However, clinicians may choose to assess the risks and benefits of patch testing for each patient given the impact of allergic contact dermatitis on patient quality of life.
Identifiants
pubmed: 33896928
doi: 10.1097/DER.0000000000000726
pii: 01206501-900000000-99476
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-374Informations de copyright
Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.
Déclaration de conflit d'intérêts
J.Y. has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. The other authors have no funding or conflicts of interest to declare.
Références
Lazzarini R, Duarte I, Ferreira AL. Patch tests. An Bras Dermatol 2013;88(6):879–888.
Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018;28(3):139–150.
Puza CJ, Atwater AR. Positive patch test reaction in a patient taking dupilumab. Dermatitis 2018;29(2):89.
Kim N, Notik S, Gottlieb AB, et al. Patch test results in psoriasis patients on biologics. Dermatitis 2014;25(4):182–190.
Wee JS, White JM, McFadden JP, et al. Patch testing in patients treated with systemic immunosuppression and cytokine inhibitors. Contact Dermatitis 2010;62(3):165–169.
Anveden I, Lindberg M, Andersen KE, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis 2004;50(5):298–303.
Olupona T, Scheinman P. Successful patch testing despite concomitant low-dose prednisone use. Dermatitis 2008;19(2):117–118.
Fowler JF Jr., Maibach HI, Zirwas M, et al. Effects of immunomodulatory agents on patch testing: expert opinion 2012. Dermatitis 2012;23(6):301–303.
Raffi J, Suresh R, Botto N, et al. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol 2020;82(1):132–138.
Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep 2018;4(9):899–904.
Zhu GA, Chen JK, Chiou A, et al. Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab. JAAD Case Rep 2019;5(4):336–338.
Raffi J, Botto N. Patch testing and allergen-specific inhibition in a patient taking dupilumab. JAMA Dermatol 2019;155(1):120–121.
Verma KK, Bhari N, Sethuraman G. Azathioprine does not influence patch test reactivity in parthenium dermatitis. Contact Dermatitis 2016;74(1):64–65.
Vena GA, Foti C, Piazzola L, et al. Can cyclosporin A help distinguish allergic from irritant patch test reactions? Contact Dermatitis 1994;31(4):256–257.
Stout M, Silverberg JI. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol 2019;81(1):157–162.
Hoot JW, Douglas JD, Falo LD Jr. Patch testing in a patient on dupilumab. Dermatitis 2018;29(3):164.
López-Jiménez EC, Marrero-Alemán G. One-third of patients with therapy-resistant atopic dermatitis may benefit after patch testing. J Eur Acad Dermatol Venereol 2019;33(10):e377–e378.
Wentworth AB, Davis MD. Patch testing with the standard series when receiving immunosuppressive medications. Dermatitis 2014;25(4):195–200.
Yfanti I, Nosbaum A, Berard F, et al. Methotrexate does not impede the development of contact allergy. Contact Dermatitis 2018;78(3):223–224.
Rosmarin D, Gottlieb AB, Asarch A, et al. Patch-testing while on systemic immunosuppressants. Dermatitis 2009;20(5):265–270.
Hamann D, Zirwas M. Successful patch testing of a patient receiving anti–interleukin-17 therapy with secukinumab: a case report. Contact Dermatitis 2017;76(6):378–379.
Burkemper NM. Contact dermatitis, patch testing, and allergen avoidance. Mo Med 2015;112(4):296–300.
Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol 2014;134(2):362–372.
Duarte I, Almeida FA, Proença NG. Excited skin syndrome. Am J Contact Dermatitis 1996;7(1):24–34.
Ale IS, Maibacht HA. Diagnostic approach in allergic and irritant contact dermatitis. Expert Rev Clin Immunol 2010;6(2):291–310.